Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer
Aug 7, 2024
01:15:00
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer.
Breast Cancer Update